Business Context and Reporting Period
Company: Ginkgo Bioworks Holdings, Inc. (NYSE: DNA)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2024
Business Overview: Ginkgo operates a horizontal platform for cell programming, offering services across two segments: Cell Engineering (R&D services for custom cell design) and Biosecurity (biomonitoring and bioinformatic support). The company is currently executing a significant restructuring plan to reduce operational expenditures, including a workforce reduction of at least 35% and facility consolidation.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $89,046 | $55,430 | $183,196 | $216,700 |
| Net Loss | $(56,403) | $(302,891) | $(439,495) | $(681,175) |
| Loss Per Share (Basic/Diluted) | $(1.08) | $(6.21) | $(8.58) | $(14.09) |
| Operating Cash Flow | — | — | $(277,150) | $(237,669) |
| Cash and Cash Equivalents (End of Period) | $616,214 | $1,049,244 | $616,214 | $1,049,244 |
| Goodwill | $0 | $49,238 | $0 | $49,238 |
Note: Q3 Operating Cash Flow is not explicitly provided in the text; only the nine-month figure is available.
Material Changes vs. Prior Period
- Revenue Growth: Q3 2024 revenue increased 61% year-over-year to $89.0 million. This was primarily driven by a $45.4 million non-cash revenue recognition from the termination of a contract with Motif FoodWorks, which released a deferred revenue balance. Cell Engineering revenue grew significantly, while Biosecurity revenue declined due to the cessation of COVID-19 testing product sales.
- Expense Reduction: Operating expenses decreased significantly due to restructuring. Research and Development (R&D) expenses dropped 51% in Q3 2024 compared to Q3 2023, and General and Administrative (G&A) expenses dropped 36%.
- Impairments: The company recorded a $47.9 million goodwill impairment charge in the first half of 2024, fully writing off the goodwill associated with the Cell Engineering reporting unit. There were no lease asset impairments in Q3 2024, compared to a $96.2 million charge in Q3 2023 related to the Zymergen facility exit.
- Restructuring: The company incurred $2.9 million in restructuring charges in Q3 2024 (totaling $20.0 million for the nine months), primarily for employee termination costs and facility consolidation.
- Stock Split: A 1-for-40 reverse stock split was effected on August 19, 2024. All share and per-share data in the filing have been retrospectively adjusted.
Guidance, Outlook, and Risks
- Restructuring Plan: Management expects to reduce labor expenses by at least 35% and consolidate facilities. Total employee termination costs are estimated between $18.0 million and $22.0 million. The plan is expected to be substantially completed in 2025.
- Liquidity: As of September 30, 2024, the company held $616.2 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least the next 12 months.
- Internal Controls: The company disclosed a material weakness in internal control over financial reporting that remains present as of September 30, 2024. Remediation efforts are ongoing, including employee training and automation of control processes.
- Strategic Shifts: The company is shifting its Biosecurity focus from COVID-19 testing to global surveillance programs. In Cell Engineering, the company is launching new AI-driven offerings (Ginkgo Datapoints) and has modified commercial terms for some customers to remove downstream value share in certain program types.
- Risks: Key risks include the ability to realize cost savings from restructuring, the volatility of equity investments in customers, and the potential for further asset impairments related to facility consolidation.
Investor Verification Checklist
- Non-Cash Revenue Impact: Verify the sustainability of revenue growth given that $45.4 million of Q3 revenue was a one-time non-cash release from the Motif contract termination.
- Restructuring Execution: Monitor the timeline and actual costs of the workforce reduction and facility subleasing, as delays could impact cash flow and cost savings targets.
- Internal Control Remediation: Track progress on the material weakness in internal controls, as this affects the reliability of future financial reporting.
- Cash Burn Rate: Assess the trajectory of operating cash burn ($277 million for 9M 2024) against the $616 million cash balance to determine runway.
- Investment Portfolio: Review the valuation and impairment status of equity investments in Platform Ventures (e.g., Motif, Genomatica, Synlogic), which have historically contributed to losses.